Levetiracetam Ratiopharm

Levetiracetam, the active ingredient in Levetiracetam Ratiopharm, is an anticonvulsant presented as a tablet for oral use. It is indicated for the control of partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, and is marketed throughout the European Union.

GNH USA supplies Levetiracetam Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, providing reliable access to this EU‑approved antiepileptic medication.

Levetiracetam is an antiepileptic medication used to manage seizure disorders. - Partial seizures: decreases the occurrence of focal onset seizures, improving seizure control and quality of life for patients with localized epileptic activity. - Generalized tonic‑clonic seizures: lowers the risk of full‑body convulsive episodes, aiding in the stabilization of patients with widespread seizure activity. - Myoclonic seizures: mitigates rapid, shock‑like muscle jerks, providing therapeutic benefit for patients with juvenile myoclonic epilepsy and related conditions.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes including agitation. - Nausea: feeling of stomach upset, sometimes with vomiting. - Nasal congestion: mild blockage or runny nose. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Blood disorders: thrombocytopenia or leukopenia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering and detachment.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose in patients with reduced kidney function. - Pregnancy: category B1, use only if benefit outweighs risk. - Breastfeeding: monitor infant for possible effects; consider alternatives. - Psychiatric history: observe for mood changes or suicidal ideation. - Concomitant CNS depressants: may enhance sedation or dizziness. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile. Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: similar enzyme‑inducing effect leading to lower levetiracetam concentrations. Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring monitoring for toxicity. - Sedative agents (e.g., benzodiazepines, alcohol): additive CNS depression, watch for excessive sedation. - Oral contraceptives: limited data, monitor for potential reduced contraceptive efficacy. - Antidepressants (e.g., SSRIs): possible increased risk of behavioral changes, observe patient.